BRPI0116757B8 - composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória - Google Patents

composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória

Info

Publication number
BRPI0116757B8
BRPI0116757B8 BRPI0116757A BR0116757A BRPI0116757B8 BR PI0116757 B8 BRPI0116757 B8 BR PI0116757B8 BR PI0116757 A BRPI0116757 A BR PI0116757A BR 0116757 A BR0116757 A BR 0116757A BR PI0116757 B8 BRPI0116757 B8 BR PI0116757B8
Authority
BR
Brazil
Prior art keywords
composition
treatment
formulation
infections caused
aerosol
Prior art date
Application number
BRPI0116757A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0116757A (pt
BR0116757B1 (pt
Inventor
Bruce Montgomery Alan
Original Assignee
Corus Pharma Inc
Gilead Sciences Inc
Salus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0116757(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corus Pharma Inc, Gilead Sciences Inc, Salus Pharma Inc filed Critical Corus Pharma Inc
Publication of BR0116757A publication Critical patent/BR0116757A/pt
Publication of BR0116757B1 publication Critical patent/BR0116757B1/pt
Publication of BRPI0116757B8 publication Critical patent/BRPI0116757B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
BRPI0116757A 2000-12-27 2001-12-20 composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória BRPI0116757B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
US60/258,423 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (3)

Publication Number Publication Date
BR0116757A BR0116757A (pt) 2003-11-04
BR0116757B1 BR0116757B1 (pt) 2014-02-04
BRPI0116757B8 true BRPI0116757B8 (pt) 2021-05-25

Family

ID=22980480

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0116757A BRPI0116757B8 (pt) 2000-12-27 2001-12-20 composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória

Country Status (19)

Country Link
US (6) US6660249B2 (enExample)
EP (2) EP2301524B1 (enExample)
JP (1) JP4646489B2 (enExample)
AT (1) ATE502623T1 (enExample)
AU (1) AU2002231244B2 (enExample)
BE (1) BE2011C029I2 (enExample)
BR (1) BRPI0116757B8 (enExample)
CA (2) CA2708703C (enExample)
CY (2) CY1111571T1 (enExample)
DE (2) DE60144291D1 (enExample)
DK (2) DK1353647T3 (enExample)
ES (2) ES2406405T3 (enExample)
FR (1) FR11C0030I2 (enExample)
IL (3) IL156596A0 (enExample)
LU (1) LU91851I2 (enExample)
NL (1) NL300492I2 (enExample)
NO (3) NO329643B1 (enExample)
PT (2) PT2301524E (enExample)
WO (1) WO2002051356A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
WO2004013133A1 (en) 2002-08-05 2004-02-12 TEVA Gyógyszergyár Részvénytársaság Preparation of aztreonam
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
US7883031B2 (en) * 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
JP4741487B2 (ja) * 2003-07-02 2011-08-03 コーラス ファーマ，インコーポレイティド アズトレオナムｌ−リジン及びそれを調製するための方法
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
JP2008505189A (ja) 2005-05-09 2008-02-21 シコール インコーポレイティド アズトレオナムの製造方法
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
WO2009020481A2 (en) * 2007-05-08 2009-02-12 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
BRPI0817636A2 (pt) * 2007-10-01 2019-09-24 Gilead Sciences Inc aztreonam lisina inalada para o tratamento de déficits na qualidade de vida relacionada à saúde em doenças pulmonares
CN104189908B (zh) * 2007-11-27 2017-01-11 阿尔吉法玛公司 包含藻酸盐低聚物的产品、包含无生命表面的产品和清创组合物
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
JP5202764B2 (ja) 2009-06-03 2013-06-05 アルギファルマ エーエス 細菌における多剤耐性の克服に使用されるアルギネートオリゴマー
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
EP2804589A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
CA2910825A1 (en) * 2013-03-28 2014-10-02 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
US11285284B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
WO2017192782A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
EP3452150B1 (en) 2016-05-03 2024-01-17 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system
EP4624054A3 (en) 2016-05-03 2025-11-19 Pneuma Respiratory, Inc. Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
JP2020536614A (ja) 2017-10-04 2020-12-17 ニューマ・リスパイラトリー・インコーポレイテッド 呼吸により電気的に作動するインライン液滴送達装置および使用方法
US11458267B2 (en) 2017-10-17 2022-10-04 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
CN111479604B (zh) 2017-11-08 2022-12-30 精呼吸股份有限公司 具有小体积安瓿的电动呼吸致动直列液滴输送装置及使用方法
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
US12208061B2 (en) * 2019-02-28 2025-01-28 Exorao Life Science S.R.L. Sterile aztreonam package
AU2020399803A1 (en) 2019-12-11 2022-06-23 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
EP4659870A2 (en) 2021-06-22 2025-12-10 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US12161795B2 (en) 2022-07-18 2024-12-10 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US572801A (en) * 1896-12-08 Telephone-exchange
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
AU703192B2 (en) * 1994-01-14 1999-03-18 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU725733B2 (en) 1996-09-04 2000-10-19 Takara Bio Inc. Fungal antigens and process for producing the same
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
CN1348377A (zh) * 1998-12-17 2002-05-08 希龙公司 用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
JP2003502292A (ja) 1999-06-01 2003-01-21 バイオジェン インコーポレイテッド ヘッジホッグタンパク質のポリマー結合体及び利用
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
EP1666028B1 (en) * 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
JP2005505441A (ja) * 2001-10-08 2005-02-24 カリフォルニア インスティテュート オブ テクノロジー 微小加工レンズ、その製造の方法および応用
EP1438019A1 (en) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US20040009126A1 (en) 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
JP4741487B2 (ja) 2003-07-02 2011-08-03 コーラス ファーマ，インコーポレイティド アズトレオナムｌ−リジン及びそれを調製するための方法
BRPI0817636A2 (pt) 2007-10-01 2019-09-24 Gilead Sciences Inc aztreonam lisina inalada para o tratamento de déficits na qualidade de vida relacionada à saúde em doenças pulmonares

Also Published As

Publication number Publication date
US6660249B2 (en) 2003-12-09
CY2011012I1 (el) 2014-04-09
NO2011001I1 (no) 2011-02-07
JP2004516302A (ja) 2004-06-03
DE122011100043I1 (de) 2011-12-15
CA2708703C (en) 2012-12-04
NO20032946L (no) 2003-08-26
IL221036A0 (en) 2012-08-30
US9533000B2 (en) 2017-01-03
IL156596A0 (en) 2004-01-04
CY1111571T1 (el) 2014-04-09
US20140037735A1 (en) 2014-02-06
NO20101377L (no) 2003-08-26
ATE502623T1 (de) 2011-04-15
NL300492I2 (nl) 2017-11-02
NO329643B1 (no) 2010-11-22
ES2406405T3 (es) 2013-06-06
US20080050439A1 (en) 2008-02-28
PT1353647E (pt) 2011-05-24
EP1353647A4 (en) 2007-05-09
US20120093890A1 (en) 2012-04-19
NO20032946D0 (no) 2003-06-26
ES2360692T3 (es) 2011-06-08
BR0116757A (pt) 2003-11-04
PT2301524E (pt) 2013-07-10
EP1353647A2 (en) 2003-10-22
IL156596A (en) 2012-07-31
DK1353647T3 (da) 2011-06-14
AU2002231244B2 (en) 2006-06-29
US7208141B2 (en) 2007-04-24
US20050129623A1 (en) 2005-06-16
CA2433280A1 (en) 2002-07-04
WO2002051356A3 (en) 2002-10-31
US20030055034A1 (en) 2003-03-20
CA2708703A1 (en) 2002-07-04
LU91851I2 (fr) 2011-10-03
EP2301524B1 (en) 2013-04-24
DE60144291D1 (de) 2011-05-05
EP1353647B1 (en) 2011-03-23
CA2433280C (en) 2010-09-21
NO2011001I2 (no) 2013-05-27
WO2002051356A2 (en) 2002-07-04
CY2011012I2 (el) 2014-04-09
BR0116757B1 (pt) 2014-02-04
FR11C0030I2 (fr) 2012-03-16
LU91851I9 (enExample) 2019-01-03
US20170296517A1 (en) 2017-10-19
JP4646489B2 (ja) 2011-03-09
FR11C0030I1 (enExample) 2011-09-23
BE2011C029I2 (enExample) 2021-07-26
DK2301524T3 (da) 2013-07-15
EP2301524A1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BRPI0116757B8 (pt) composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
US8980226B2 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
AU2025256218A1 (en) Method For Reducing Lung Infection
Shah Progress in the treatment of pulmonary disease in cystic fibrosis
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: SALUS PHARMA, INC. (US)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE TRANSFERENCIA NO 004866/SP DE 18/03/2005, QUEIRA APRESENTAR DOCUMENTO DE CESSAO ONDE CONSTE O NUMERO DO PEDIDO BRASILEIRO A SER TRANSFERIDO, ASSINADO PELA CEDENTE, CESSIONARIA E DUAS TESTEMUNHAS, COM AS DEVIDAS ASSINATURAS NOTARIZADAS E COM A RESPECTIVA LEGALIZACAO CONSULAR.

B25B Requested transfer of rights rejected

Owner name: SALUS PHARMA, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA DE TITULAR SOLICITADO ATRAVES DA PETICAO NO 004866/SP DE 18/03/2005, POR NAO CUMPRIMENTO DE EXIGENCIA PUBLICADA NA RPI 1865 DE 03/10/2006.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CORUS PHARMA, INC. (US)

Free format text: TRANSFERIDO POR FUSAO DE: SALUS PHARMA, INC.

B25A Requested transfer of rights approved

Owner name: GILEAD SCIENCES, INC. (US)

Free format text: TRANSFERIDO POR FUSAO DE: CORUS PHARMA, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NA PETICAO INPI/DESP NO 018110035272 DE 12/09/2011

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/12/2021